PCSK9 and atherosclerosis: Only 18.2% of our patients with DM and ASCVD were on high-intensity statins, and only 9.1%, 1.3%, and 1.7% were on ezetimibe, PCSK9 inhibitors, and icosapent ethyl, respectively.